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Ca2+/calmodulin-dependentproteinkinase II (CaMKII)
is central to synaptic transmission. Here we show
that synaptic CaMKIIa binds to the N-terminal region
of the third intracellular loop of the limbic dopamine
D3 receptor (D3R). This binding is Ca2+ sensitive
and is sustained by autophosphorylation of CaMKII,
providing an unrecognized route for the Ca2+-medi-
ated regulation of D3Rs. The interaction of CaMKIIa
with D3Rs transforms D3Rs into a biochemical
substrate of the kinase and promotes the kinase to
phosphorylate D3Rs at a selective serine site (S229).
In accumbal neurons in vivo, CaMKIIa is recruited to
D3Rs by rising Ca2+ to increase the CaMKIIa-medi-
ated phosphorylation of D3Rs, thereby transiently
inhibiting D3R efficacy. Notably, the D3R inhibition
is critical for integrating dopamine signaling to
control behavioral sensitivity to the psychostimulant
cocaine. Our data identify CaMKIIa as a recruitable
regulator of dopamine receptor function. By binding
and phosphorylating limbic D3Rs, CaMKIIa modu-
lates dopamine signaling and psychomotor function
in an activity-dependent manner.
INTRODUCTION
Dopamine is a major neurotransmitter in the mammalian brain.
This transmitter exerts its pleiotropic actions through interactions
with two classes of dopamine receptors: the D1 class (D1 and
D5 subtypes) and the D2 class (D2, D3, and D4 subtypes). The
former is coupled to Gas-proteins, whereas the latter is generally
coupled to Gai/o-proteins. Through Gai/o-proteins, the D2 class
of receptors inhibits adenylyl cyclase and thedownstream forma-
tion of cAMP (Neve et al., 2004). Remarkably, among all dopa-
mine receptor subtypes, the dopamine D3 receptor (D3R), one
of the lesser-investigated subtypes, shows a unique distribution
pattern in the forebrain. D3Rs are preferentially expressed in themesolimbic dopaminergic projection areas, including the
nucleus accumbens (NAc) (Sokoloff et al., 1990; Bouthenet
et al., 1991). This specific localization of D3Rs suggests a signifi-
cant role of the receptor in the control of reward, motivation,
cognition, emotion, and extrapyramidal motor functions. More-
over, malfunction of D3Rs has been frequently associated with
the pathogenesis of various mental illnesses such as schizo-
phrenia, depression, and substance addiction (reviewed in Heid-
breder et al., 2005; Sokoloff et al., 2006; Richtand, 2006).
Ca2+/calmodulin-dependent protein kinase II (CaMKII) is an
enzyme that is abundant in brain cells, especially at synaptic
sites (Kelly et al., 1984). The enzyme is removed from its autoin-
hibitory state and activated by the binding of Ca2+ and calmod-
ulin (CaM). Activated CaMKII accesses and phosphorylates not
only exogenous substrates but also its own autophosphorylation
site (T286 in the a isoform) within the autoregulatory domain. The
autophosphorylation renders a Ca2+/CaM-independent (autono-
mous) kinase activity even after the initial Ca2+ stimulus subsides
(Hudmon and Schulman, 2002; Colbran and Brown, 2004; Grif-
fith, 2004). As such, CaMKII integrates and prolongs the informa-
tion conveyed by diverse forms of Ca2+ transients and serves as
a dynamic regulator that decodes activity-dependent Ca2+
signals into various forms of synaptic activity and plasticity
(reviewed in Hudmon and Schulman, 2002; Lisman et al., 2002;
Colbran and Brown, 2004).
The multifunctional nature of CaMKII also stems from its inter-
actions with various binding partners in defined subcellular
regions (Colbran, 2004). Through direct protein-protein interac-
tions, CaMKII vigorously regulates expression and function of
interacting partners and vice versa. In searching for new targets
of CaMKII at synaptic sites, we identify the limbic D3R as a direct
substrate of CaMKII. We show that CaMKIIa interacts directly
with the N-terminal region of the third intracellular loop of D3Rs
in a Ca2+- and autophosphorylation-sensitive manner in vitro.
This interaction allows CaMKII to phosphorylate D3Rs at a selec-
tive serine residue. In accumbal neurons in vivo, Ca2+ stimulates
the association of CaMKII with D3Rs and increases serine phos-
phorylation of D3Rs, resulting in suppression of D3R function.
The CaMKII-mediated inhibition of D3Rs plays a significant role
in regulating behavioral responsiveness to cocaine. Collectively,Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 425
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Regulation of D3 Receptors by CaMKIIour results demonstrate a new synaptic model for the activity-
dependent regulation of limbic D3Rs by CaMKII.
RESULTS
CaMKIIa Directly Binds to D3Rs In Vitro
D3Rs contain a large third intracellular domain that is a main site
for protein-protein interactions (Figure S1 available online). To
search for new proteins that bind to this domain, we prepared
glutathione-S-transferase (GST)-fusion proteins containing the
second or third intracellular loop of rat D3Rs, D3RIL2 or D3RIL3
(Figure 1A), and used them as immobilized (GST-bound) baits
to screen NAc lysates in pull-down assays. We found a protein
(50 kDa) that was specifically precipitated by GST-D3RIL3,
but not by GST alone (Figure 1B) or GST-D3RIL2 (data not
shown). This protein was subsequently identified as CaMKIIa
by mass spectrometry. Immunoblot analysis confirmed that
GST-D3RIL3, but not GST-D3RIL2 or GST alone, precipitated
CaMKIIa (Figure 1C). Neither the GST-fusion proteins nor GST
precipitated CaMKIV, another isoform of CaMK (Figure 1C).
This indicates the selectivity of D3Rs in the interaction with
CaMKII. To identify the specific CaMKIIa region responsible
for the interaction with D3Rs, GST-fusion proteins were
prepared from three major structures of CaMKIIa: the N-terminal
catalytic domain (GST-CaMKIIaCD), the regulatory domain (GST-
CaMKIIaRD), and the C-terminal association domain (GST-
CaMKIIaAD) (Figure 1D). We found that GST-CaMKIIaCD precip-
Figure 1. Association of CaMKIIawith D3Rs
(A) GST-fusion proteins derived from rat D3Rswith
seven transmembrane (TM) domains.
(B) Coomassie staining of a gel resolved from pull-
down assays with rat accumbal lysates. An open
arrow indicates a protein (50 kDa) pulled down
by GST-D3RIL3.
(C) GST-D3RIL3 precipitated CaMKIIa from rat
accumbal lysates.
(D) GST-fusion proteins derived from rat CaMKIIa.
(E and F) GST-CaMKIIa and GST-CaMKIIaCD
precipitated D3Rs (E), but not D1Rs (F), from rat
accumbal lysates.
(G) GST-fusion proteins derived from D3RIL3.
(H–J) Results from in vitro binding assays with
GST-fusion proteins and purified CaMKIIa (H and
I) or D3RIL3 (J).
Precipitated proteins from pull-down assays (C, E,
and F) and proteins bound to CaMKIIa or D3RIL3
from in vitro binding assays (H–J) were visualized
with immunoblots (IB) using the specific anti-
bodies as indicated.
itated D3Rs in accumbal lysates,
whereas GST-CaMKIIaRD, GST-CaM-
KIIaAD, and GST-CaMKIV did not
(Figure 1E). None of the GST-fusion
proteins precipitated dopamine D1
receptors (D1Rs) (Figure 1F). Thus, the
primary CaMKIIa region for the interac-
tion with D3Rs is restricted to CaMKIIaCD.
All blots were probed in parallel with a GST antibody to ensure
equivalent protein loading (data not shown).
To define whether the CaMKIIa-D3R interaction is direct, and
to reveal the accurate region of D3RIL3 involved in the interaction,
we conducted in vitro binding assays with purified proteins
(Figure 1G–1J). We found that CaMKIIa bound to immobilized
GST-D3RIL3 and GST-D3RIL3(R210-P239), but not to other
GST-D3RIL3 fragments (Figure 1H). No CaMKIIa bound to GST-
D2RIL3(I210-V270) (Figure 1I). In the reverse experiment, D3RIL3
bound to immobilized GST-CaMKIIa and GST-CaMKIIaCD, but
not to GST-CaMKIIaRD, GST-CaMKIIaAD, or GST-CaMKIV
(Figure 1J). These results demonstrate that CaMKIIa directly
binds to D3Rs in vitro. The R210-P239 fragment, a 30 amino
acid region at the N terminus of D3RIL3, contains a site critical
for binding to the catalytic domain of CaMKIIa.
Ca2+ Enhances the Binding of CaMKIIa to D3Rs
Binding of Ca2+/CaM to the regulatory domain of CaMKII is an
essential step for releasing autoinhibition and activating the
enzyme. Thus, Ca2+ usually regulates the binding properties of
CaMKII (Bayer et al., 2001; Colbran and Brown, 2004). To deter-
mine if Ca2+ affects the CaMKIIa association with D3Rs, we
tested the capacity of CaMKIIa to bind toGST-D3RIL3 in the pres-
ence of Ca2+, CaM, or both. Similar to the results from the above
in vitro binding assays performed in the absence of exogenously
added Ca2+/CaM, CaMKIIa showed a low level of constitutive
binding to GST-D3RIL3 (L1 in Figure 2A). Interestingly, the addi-
tion of Ca2+ (0.5 mM) and CaM (1 mM) together, but not Ca2+ or426 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.
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to D3RIL3 (L4 versus L2 and L3 in Figures 2A and 2B). This
increase was prevented by adding the Ca2+ chelator EGTA at
1 mM (L5 in Figure 2A), and could occur to CaMKIIa that was
not autophosphorylated at T286, as evidenced by the fact that
no T286-autophosphorylatedCaMKIIa (pCaMKIIa) was detected
in these binding assays with a phospho-specific antibody, due to
the absence of ATP throughout the reaction (middle panel of
Figure 2A). These results demonstrate that activation of CaMKIIa
by Ca2+/CaM was sufficient to enhance its affinity for D3Rs.
Consistent with this, an increase in the CaMKIIa-D3RIL3 binding
was observed only with the wild-type (WT) CaMKIIa, but not
with the Ca2+/CaM binding-defective CaMKIIa mutant T305/
306D (Figures 2C and 2D) (Colbran and Soderling, 1990). More-
over, a peptide fragment (L290-A309) that corresponds to the
CaM binding domain of CaMKII, and thereby antagonizes the
CaM-CaMKII binding, blocked the Ca2+/CaM-induced enhance-
ment of the CaMKIIa binding to D3Rs (Figure 2E). To determine if
CaM itself binds to D3RIL3, we conducted in vitro binding assays
with purified CaM. No binding of CaM toGST-D3RIL3 or GSTwas
Figure 2. Ca2+/CaM-Regulated CaMKIIa
Binding to D3RIL3
(A and B) Addition of Ca2+/CaM increased the
CaMKIIa binding to GST-D3RIL3. Note that, in the
middle panel of Figure 2A, CaMKIIa was not auto-
phosphorylated at T286 in binding assays lacking
ATP (L1-L6) as opposed to T286-autophosphory-
lated CaMKIIa detected in the synaptosomal
fraction (P2) from the rat NAc (L8) with a phos-
pho-specific antibody. (C and D) Addition of
Ca2+/CaM did not alter the binding of CaMKIIa
T305/306D mutant to GST-D3RIL3. (E) Coaddition
of an inhibitory peptide (L290-A309) prevented
an increase in the CaMKIIa-D3RIL3 binding
induced by Ca2+/CaM. (F) CaM did not bind to
GST-D3RIL3 or GST, whereas it bound to GST-
CaMKIIa in a Ca2+-dependent manner. Binding
assays were performed between His-tagged
WT CaMKIIa (57 kDa), T305/306D mutant
(50 kDa), or CaM proteins and immobilized
GST, GST-D3RIL3, or GST-CaMKIIa in the pres-
ence or absence of CaCl2 (0.5 mM), CaM (1 mM),
EGTA (1 mM), or L290-A309 (5 mM). Data are pre-
sented as means ± SEM for three to six experi-
ments per group. *p < 0.05 versus L1.
observed, whereas CaM bound to GST-
CaMKIIa in a Ca2+-dependent fashion
(Figure 2F).
Autophosphorylation of CaMKIIa
Further Enhances the Binding
of CaMKIIa to D3Rs
Activation of CaMKIIa by Ca2+/CaM
results in autophosphorylation at T286 in
the regulatory domain of adjacent CaM-
KIIa subunits, which ‘‘traps’’ CaM and
keeps the enzyme in a catalytically active
conformation, an autonomous (Ca2+/
CaM-independent) activity, even after the initial Ca2+/CaM signal
subsides (Meyer et al., 1992). A series of experiments was
carried out to determine the influence of T286 autophosphoryla-
tion on the CaMKIIa-D3R binding. The unphosphorylated WT
kinase exhibited constitutive and enhanced binding to D3RIL3
in the absence and presence of Ca2+/CaM, respectively
(Figure 3A). Interestingly, WT CaMKIIa that was activated by
Ca2+/CaM and autophosphorylated at T286 prior to the binding
assays showed a further enhanced level of binding (L3 and
L4 in Figure 3A) as compared with unphosphorylated WT,
regardless of the presence or absence of Ca2+/CaM in the
binding assays (Figures 3A and 3D). An autophosphorylation-
defective mutant, T286A, showed the same level of binding to
D3Rs in the presence or absence of ATP (Figures 3B and 3D).
In contrast, a constitutively active (Ca2+/CaM-independent)
mutant, T286D, that shares the property of autophosphorylated
CaMKIIa, showed a high level of binding to D3Rs, which was not
affected by the addition of Ca2+/CaM or Ca2+/CaM/ATP (Figures
3C and 3D). These data indicate that, while the basal (unstimu-
lated) and Ca2+/CaM-stimulated binding to D3Rs requires noNeuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 427
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increases the capacity of CaMKIIa to bind to D3Rs.
The binding properties of autophosphorylated CaMKIIa were
further analyzed in binding assays with EGTA (1 mM) added at
different times. As before, an increased amount of D3RIL3-bound
CaMKIIa was detected when Ca2+/CaM and ATP were added for
20 min (L3 in Figure 3E). The addition of EGTA substantially
inhibited the CaMKIIa binding. However, this inhibition occurred
only when EGTA was added in the early phase (<2 min, L4–L6 in
Figure 3E). When the binding reaction lasted long enough
(2–15 min), EGTA was no longer effective (L7 and L8 in
Figure 3E). The D3RIL3-bound enzyme from the ATP-containing
assayswasautophosphorylatedat T286, and the level of this auto-
phosphorylation paralleled well with the capacity of the enzyme in
binding toD3Rs at different EGTA-adding times (Figure 3E). These
data suggest that the CaMKIIa binding to D3Rs and T286 auto-
phosphorylation are initially reversible, but become Ca2+/CaM
independent when the kinase transforms to an autonomous state.
Figure 3. Influence of T286 Autophosphory-
lation on CaMKIIa-D3RIL3 Binding
(A–C) Binding of WT CaMKIIa/pCaMKIIa (A),
mutant T286A (B), or mutant T286D (C) to GST-
D3RIL3.
(D) A graph of the data from (A)–(C). Blue and red
bars represent changes in lane 2 (L2) and lane 4
(L4), respectively, over lane 1 (L1). *p < 0.05 versus
L1. +p < 0.05 versus L2.
(E) Effects of EGTA added at different times on the
CaMKIIa binding toGST-D3RIL3. EGTAwas added
0, 0.5, 1, 2, or 15 min after the onset of the binding
reaction. Representative immunoblots are shown
above the quantified data.
(F) pCaMKIIa bound to GST-D3RIL3 and the GST-
D3RIL3(R210-P239) fragment.
(G) Effects of six peptides derived from the R210-
P239 fragment on the binding of pCaMKIIa to
GST-D3RIL3(R210-P239). The first 30 amino acid
sequence of D3RIL3 is shown. Bold letters (in red)
indicate the potential CaMKIIa binding motif.
Binding assays were performed between His-
tagged WT CaMKIIa (57 kDa), WT pCaMKIIa
(57 kDa), T286A mutant (50 kDa), or T286D
mutant (50 kDa) proteins and immobilized GST-
D3RIL3 or GST-D3RIL3(R210-P239) in the presence
or absence of CaCl2 (0.5 mM), CaM (1 mM), ATP
(50 mM), or EGTA (1 mM) as indicated. Bound
CaMKIIa, pCaMKIIa, or mutants were visualized
by immunoblots. Data are presented as means ±
SEM for four to six experiments per group.
Like the unphosphorylated enzyme,
autophosphorylated CaMKIIa bound to
the same N-terminal region (R210-P239)
of D3RIL3 (Figure 3F). This region was
therefore further analyzed to identify
a sufficient binding motif. A panel of
peptides derived from this region was
used to compete with the R210-P239
fragment for binding to CaMKIIa. It was
found that four out of six peptides (P1,
P2, P3, and P5) blocked the binding of GST-D3RIL3(R210-
P239) to active CaMKIIa (Figure S2A) or autophosphorylated
CaMKIIa (Figure 3G). These four peptides, when used in
a biotinylated form, pulled down CaMKIIa (Figure S2B). Thus,
a 14 residue motif (RILTRQNSQCISIR) contained by all four
peptides constitutes a core motif for CaMKIIa binding. Notably,
this motif is highly conserved among mammals.
CaMKII Phosphorylates S229 in D3RIL3
A comparison of the amino acid sequences revealed a remark-
able homology between the CaMKIIa-binding region in D3RIL3
and the sequences spanning a T286 pseudosubstrate region in
CaMKIIa (Yang and Schulman, 1999), S1303 in NR2B (Strack
et al., 2000), and an S/T site in two classical CaMKII substrates,
autocamtide-2 and syntide-2 (Figure 4A). This suggested that
D3RIL3 might serve as a phosphorylation substrate of CaMKII.
Indeed, CaMKIIa phosphorylated GST-D3RIL3, but not GST, in
the presence of Ca2+/CaM (Figure 4B). Similarly, CaMKIIa428 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.
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ure 4C). This phosphorylation was rapid (Figure 4D) and
comparable to the phosphorylation of an NR2B fragment
(Figure S3A). The kinetic parameter, Km, was notably low,
65.9 ± 1.2 nM (Figure 4E), suggesting that D3RIL3, likeNR2B (Om-
kumar et al., 1996), acts as a high-affinity substrate. This high-
affinity nature implies that phosphorylation of D3RIL3 could
occur under physiological conditions. In support of this, GST-
D3RIL3(R210-P239) was phosphorylated at two physiological
Ca2+ concentrations (Figure S3B).
To identify accurate phosphorylation sites within the R210-
P239 fragment, we used a series of synthetic peptides with or
without mutations of two known serine sites in this fragment
(S229 and S233). Figure 4F shows that theWT S229/233 peptide
substrate was phosphorylated by CaMKIIa to a considerable
stoichiometry (0.81mol of phosphate/mol of substrate). Mutation
of S233 to alanine (S233A) did not affect the phosphorylation. In
contrast, mutation of S229 to alanine (S229A) or S229/233 to
alanine (S229/233A) completely abolished the phosphorylation.
Thus, S229 rather than S233 or T225 is the site of phosphoryla-
tion. The fact that S229 lies within the CaMKII binding motif in
D3RIL3 and aligns with a phospho-S/T site predicted from the
consensus CaMKII phosphorylation sequence, (I/L)XRXX(S/T)
(White et al., 1998), is noteworthy. The results from tandem
mass spectrometry analysis of tryptic digests of CaMKII-phos-
phorylated GST-D3RIL3 conclusively identified S229 as a phos-
phorylation site (data not shown).
Although the CaMKIIa binding domain in D3RIL3 aligns with the
substrate recognitionmotif andcontainsahigh-affinityphosphor-
ylation site (S229), a classical enzyme-substrate binding mecha-
nism does not appear to be involved in the CaMKIIa binding to
D3RIL3. This is supported by the finding that syntide-2 (a model
peptide substrate for CaMKII) at concentrations up to 400 mM
(>30 times theKm for phosphorylation;Hashimoto andSoderling,
1987) failed to compete for the CaMKIIa binding to D3RIL3
(Figure S3C).
CaMKIIa Interacts with D3Rs In Vivo
D3Rs are enriched in accumbal neurons. To determine whether
native CaMKIIa and D3Rs interact with each other in these
neurons, coimmunoprecipitation was performed using the solu-
bilized synaptosomal fraction (P2) from the rat NAc. A clear and
specific band of CaMKIIa, but not CaMKIV, was shown in the
D3R precipitates (Figure 5A). No immunoreactivity of other
key synaptic proteins, including postsynaptic density (PSD)-
93, PSD-95, synapse-associated protein (SAP) 97, and SAP102,
was detected in the D3R precipitates (data not shown). In
a reverse coimmunoprecipitation assay, a D3R-specific band
was seen in the CaMKIIa precipitates (Figure 5B). CaMKIIa in
D3R-expressing neurons of the rat midbrain structures (sub-
stantia nigra and ventral tegmental area) and the rat medial
mammillary bodies showed no interaction with D3Rs because
no coimmunoprecipitation between the two proteins was seen
in the P2 fraction from these regions (Figures 5C and 5D). In the
Figure 4. Phosphorylation of D3RIL3 by
CaMKIIa In Vitro
(A) Alignment of CaMKII phosphorylation
sequences from different substrates. The key resi-
dues shaded in gray are contacted electrostati-
cally or hydrophobically by the residues (E243,
F98, D238, W237, V208, K105, and I205) from
the catalytic domain of CaMKII.
(B) Autoradiographs illustrating phosphorylation of
GST-D3RIL3 (upper), but not GST (lower), in the
presence of Ca2+/CaM.
(C) An autoradiograph illustrating phosphorylation
of GST-D3RIL3 and GST-D3RIL3(R210-P239).
(D) Time course of D3RIL3(R210-P239) phosphory-
lation.
(E) Kinetic analysis of D3RIL3(R210-P239) phos-
phorylation. The inset table shows the kinetic
parameters.
(F) Phosphorylation of synthetic peptides (WT or
mutants). An autoradiograph shows phosphoryla-
tion of three peptides.
Phosphorylation stoichiometry (means ± SEM)
was calculated from the radioactivity measured
on Coomassie-stained bands by liquid scintillation
counting. Substrate proteins at 0.1 mM (B, C, D,
and F) or increased concentrations (E) were incu-
bated at 30C for 1 min (E), 10 min (B, C, and F),
or indicated times (D) with [g-32P]ATP and
CaMKIIa in the presence of Ca2+ (0.5 mM)/CaM
(1 mM) (C, D, E, and F) or as indicated (B). The solid
arrows (B, C, and F) indicate autophosphorylated
CaMKIIa whereas open arrows (B and C) indicate
phosphorylated GST-D3RIL3.Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 429
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(A andB) Coimmunoprecipitation (IP) of CaMKIIa andD3Rs in the synaptosomal fraction from the rat NAc. Lanes 3 and 4 showed no specific bands due to the lack
of any antibody (L3) and the use of an irrelevant IgG (L4).
(C and D) No coimmunoprecipitation of CaMKIIa and D3Rs was detected in the synaptosomal fraction from the rat substantia nigra (SN)/ventral tegmental area
(VTA) and medial mammillary bodies (MMB).
(E) Ionomycin (15 min) concentration-dependently increased the association of CaMKIIa and pCaMKIIa(T286) with D3Rs.
(F) KN93 blocked the effect of ionomycin. Ionomycin (10 mM) was cotreated with KN93 or KN92 (20 mM) for 15 min.
(G) Tat-CaMKIINtide blocked the effect of ionomycin. Tat-CaMKIINtide (5 mM) was applied 1 hr prior to ionomycin (10 mM, 15 min).
(H) Tat-D3Rr blocked the ionomycin-induced association of CaMKIIa with D3Rs.
(I) Tat-D3Rr blocked the ionomycin-stimulated serine phosphorylation of D3Rs.
Tat peptides (5–10 mM) were applied 1 hr prior to ionomycin (10 mM, 15 min). Immunoblots (IB) of CaMKIIa, pCaMKIIa(T286), phosphoserine, or D3Rs were per-
formed on D3R precipitates from drug-treated accumbal slices (E–I). Data are presented asmeans ± SEM for three or five experiments per group. *p < 0.05 versus
vehicle or vehicle + vehicle. +p < 0.05 versus vehicle + ionomycin.430 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.
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Regulation of D3 Receptors by CaMKIIFigure 6. Regulation of CaMKIIa-D3R Interactions by Glutamate and Dopamine Receptors and VOCCs
(A) Glutamate increased the CaMKIIa-D3R interaction.
(B) MK801 and KN93, but not GYKI52466 and KN92, blocked the CaMKIIa-D3R interaction induced by glutamate.
(C) NMDA increased the CaMKIIa-D3R interaction.
(D) The time course of the NMDA-stimulated CaMKIIa-D3R interaction. NMDA (100 mM/glycine 10 mM) was applied for 2.5, 5, 15, 30, or 60 min.
(E) The VOCC activator FPL64176 induced a nifedipine-sensitive increase in the CaMKIIa-D3R interaction.
(F) SKF83959 elevated the CaMKIIa-D3R interaction.
Rat accumbal slices were treated with glutamate (1 or 100 mM/glycine 10 mM), NMDA (1 or 100 mM/glycine 10 mM), FPL64176 (20 mM), or SKF83959 (10 mM) alone
or with MK801 (10 mM), GYKI52466 (10 mM), KN93 (20 mM), KN92 (20 mM), nifedipine (20 mM), SCH23390 (1 mM), U73122 (20 mM), or U73343 (20 mM) for 15 min.
Tat-CaMKIINtide peptides (5 mM)were applied 1 hr prior to SKF83959 (10 mM, 15min). Immunoblots (IB) of CaMKIIa or D3Rswere performed on D3R precipitates
from drug-treated accumbal slices. Data are presented as means ± SEM for four or five experiments per group. *p < 0.05 versus vehicle or vehicle + vehicle.
+p < 0.05 versus glutamate (B), FPL64176 (E), or SKF83959 (F).NAc, the coimmunoprecipitation was seen in WT mice, but
not in D3R mutant mice (Figure S4A). Furthermore, the coim-
munoprecipitation occurred in the purified PSD fraction of rat
accumbal neurons (Figure S4B). These data indicate a region-
specific interaction between CaMKIIa and D3Rs in the NAc
in vivo and an interaction that can occur in the PSD. Further
evidence supporting the interaction of the two proteins in vivo
was obtained from yeast two-hybrid assays. Using D3RIL3 as
bait in the yeast two-hybrid system, we found a prominent
interaction between D3RIL3 and CaMKIIa (Figure S4C). The
strong interaction with CaMKIIa was also seen for theD3RIL3(R210-P239), but not D3RIL3(Q240-Q375), fragment
(Figure S4C).
To determine whether the CaMKIIa-D3R interaction is subject
to the Ca2+ regulation as was observed in vitro, we tested the
interaction in the presence of the Ca2+ ionophore, ionomycin,
in rat striatal/NAc slices. Ionomycin induced a concentration-
dependent increase in the amounts of CaMKIIa and pCaMKIIa
(T286) in the D3R precipitates (Figure 5E). The CaMK inhibitor
KN93 (20 mM), which inhibits CaMK by preventing the CaM
binding to the enzyme, blocked the ionomycin-induced binding
of CaMKIIa (Figure 5F) and pCaMKIIa(T286) (Figure S5) toNeuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 431
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Regulation of D3 Receptors by CaMKIIFigure 7. Inhibition of D3R Function by CaMKII in Rat Accumbal Slices
(A) Ionomycin antagonized the D3R-mediated inhibition of forskolin-stimulated cAMP accumulation.
(B) Tat-D3Rr reversed the effect of ionomycin.
(C) Effects of Tat-fusion peptides on dopamine-stimulated cAMP accumulation.
(D) Effects of the D1R or D3R antagonist on dopamine-stimulated cAMP accumulation.
(E) Effects of Tat-fusion peptides on dopamine-stimulated CREB phosphorylation.
(F) Effects of Tat-fusion peptides on dopamine-stimulated c-Fos expression.
(G) SKF81297 increased pGluR1-S845 levels.
(H) Effects of Tat-fusion peptides on SKF81297-stimulated GluR1 phosphorylation.
(I) A model of the Ca2+-dependent regulation of D3Rs by CaMKII. AC, adenylyl cyclase.432 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.
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5F and S5). Like KN93, the highly selective CaMKII inhibitory
peptide Tat-CaMKIINtide (Chang et al., 1998; Vest et al., 2007)
at 5 mM (1 hr before ionomycin) blocked the effect of ionomycin
(Figure 5G). These results demonstrate a Ca2+-sensitive nature
of CaMKIIa-D3R interactions in vivo.
To evaluate the role of CaMKIIa-D3RIL3 binding in vivo, we
synthesized a Tat-fusion peptide (Tat-D3Rr). The peptide
contains a Tat domain (YGRKKRRQRRR) from the human immu-
nodeficiency virus-type 1 (HIV-1) and a CaMKIIa-binding motif
(RILTRQNSQCISIRP) from D3RIL3 (Figure 5H). The arginine-en-
riched Tat domain renders cell permeability (Aarts et al., 2002;
Mao et al., 2005; Liu et al., 2006) and the CaMKIIa-binding motif
competes with D3Rs for CaMKII binding in living neurons. In
pull-down assays with biotinylated Tat-fusion peptides, Tat-
D3Rr, but not Tat-D3Rt (a sequence-scrambled control), pulled
down recombinant and endogenous CaMKIIa (Figure S6A), indi-
cating the ability of Tat-D3Rr to bind to CaMKIIa. Tat-D3Rr
(5–10 mM, 1 hr before ionomycin) substantially reduced the ion-
omycin-stimulated association of the two proteins in striatal/
NAc slices, while Tat-D3Rt did not (Figure 5H). Thus, active
CaMKIIa was directly recruited to D3RIL3 in response to Ca
2+
rises. Ionomycin was found to increase serine phosphorylation
of D3Rs as detected by an antibody selective for phosphoserine
(Figure 5I). This increase no longer occurred in slices pretreated
with Tat-D3Rr (Figure 5I) or KN93 (Figure S6B), indicating that
the interaction of active CaMKIIa with D3RIL3 is required for
the ionomycin-stimulated phosphorylation of the receptor. The
selectivity of Tat-D3Rr in disrupting the CaMKIIa-D3R interac-
tion was confirmed by the lack of its effect in interfering with
the ionomycin-stimulated CaMKIIa interaction with a number
of other CaMKII substrates, including NR2B, the cyclin-depen-
dent kinase 5 activator p35, or a-actinin-1 (Figure S7).
To identify the receptors that might provide a Ca2+ entry to
trigger the CaMKIIa association to D3Rs, we tested the effect
of glutamate receptor activation on the interaction in NAc slices.
Glutamate mimicked the effect of ionomycin in stimulating the
CaMKIIa-D3R association (Figure 6A). The effect of glutamate
was blocked by KN93 and the NMDA receptor antagonist
MK801, but not by KN92 and the AMPA receptor antagonist
GYKI52466 (Figure 6B). Thus, glutamate, through activating
NMDA receptors, elevates the CaMKIIa-D3R association. In
support of this, NMDA itself induced a concentration-dependent
and rapid increase in the association of the two proteins (Figures
6C and 6D). FPL64176, an activator of L-type voltage-operated
Ca2+ channels (VOCCs), slightly enhanced the CaMKIIa-D3R
interaction, which was blocked by the antagonist nifedipine
(Figure 6E). Together, VOCCs and especially NMDA receptors
can provide aCa2+ entry to trigger theCaMKIIa-D3Rassociation.
Activation of phosphatidylinositol (PI)-linked D1Rs (Gaq-
coupled) rather than classical cAMP-linked D1Rs (Gas-coupled)
elicits the Ca2+ release from intracellular stores through a phos-pholipase Cb (PLCb)-dependent and adenylyl-cyclase-indepen-
dent mechanism (Felder et al., 1989; Undie and Friedman, 1990).
To determine if the Ca2+ release induced by activating PI-linked
D1Rs affects the CaMKIIa-D3R interaction, we examined the
effect of activating these receptors on the interaction of the two
proteins in NAc slices. Pharmacological activation of PI-linked
D1Rs with a selective agonist SKF83959 (Jin et al., 2003)
increased the interaction of CaMKIIa with D3Rs (Figure 6F).
This increase was blocked by the D1R antagonist SCH23390,
the amino steroid PLCb inhibitor U73122 (but not its inactive
analog U73343), and Tat-CaMKIINtide (Figure 6F). Thus, the
Ca2+ release by PI-linked D1Rs possesses the ability to upregu-
late theCaMKIIa-D3R interaction. The previous data showing the
selective activation of CaMKII by PI-linked, but not cAMP-linked,
D1Rs (Zhen et al., 2004) support this notion.
CaMKIIa-D3RIL3 Interactions Downregulate
D3R Function
Activation of D3Rs inhibits the adenylyl-cyclase-mediated cAMP
formation (Ahlgren-Beckendorf and Levant, 2004; Jeanneteau
et al., 2006). We next investigated whether the binding of CaMKII
to D3RIL3 alters the D3R function in inhibiting cAMP formation. In
rat accumbal slices, theadenylyl cyclaseactivator forskolin (1mM,
20 min) markedly elevated cAMP levels above a baseline of 4.1 ±
0.3 pmol/ml. A D3R selective agonist PD128907 at low concen-
trations (1–3 nM) significantly reduced the forskolin-activated
cAMP accumulation (Figure 7A). The selectivity of PD128907
was demonstrated by the observation that the agonist, when
applied at these sufficiently low concentrations, did not alter the
forskolin effect in slices from D3R mutant mice (Figure S8).
Cotreatment with ionomycin (10 mM) antagonized the effect of
PD128907 (Figure 7A). The effect of ionomycin was sensitive to
KN93 and Tat-CaMKIINtide but not KN92 (Figure 7A). Further-
more, Tat-D3Rr (8 mM, 1 hr prior to ionomycin/PD128907)
attenuated the effect of ionomycin while Tat-D3Rt did not (Fig-
ure 7B). Neither Tat-D3Rr nor Tat-D3Rt had any effect on the
forskolin-stimulated cAMP formation or on the inhibition of
forskolin-stimulated cAMP formation by PD128907 (data not
shown). These data indicate that Ca2+-activated CaMKII associ-
ates with D3Rs and reduces D3R efficacy in inhibiting cAMP
production.
More experiments were performed in accumbal slices to
evaluate the role of CaMKII in regulating dopamine-mediated
cAMP signaling. We found that dopamine (5 mM) consistently
elevated cAMP levels. This elevation was reduced by Tat-D3Rr
(Figure 7C). Thus, CaMKII-D3R interactions inhibit the cAMP
response to dopamine. Tat-D3Rr alone did not alter basal
cAMP levels (Figure 7C), suggesting a minimal impact of
CaMKIIa-D3RIL3 interactions to D3R function under basal condi-
tions, in which relatively lower levels of basal CaMKIIa-D3RIL3
binding would be anticipated. It is noteworthy that the dopamine
concentration (5 mM) applied here is within the physiologicalPD128907 (1–3 nM), ionomycin (10 mMwith 1mMCaCl2), KN93 (20 mM), KN92 (20 mM), SCH23390 (1 mM), and/or NGB2904 (50 nM) were cotreated with forskolin
(1 mM, 20 min) or dopamine (5 mM, 20 min) in (A)–(D). In the experiments in which the Tat-fusion peptide (Tat-CaMKIINtide, Tat-D3Rr, or Tat-D3Rt) was employed,
the peptide at 5 mM (A), 1 and 8 mM (B), or 8 mM (C, E, F, and H) was applied 1 hr prior to forskolin (A and B), dopamine (C, E, and F), or SKF81297 (H). SKF81297
was incubated at 10 mM for 5–10 min (G and H). Data are presented as means ± SEM for five to seven experiments per group. *p < 0.05 versus forskolin alone
(A and B), vehicle (G), or vehicle + vehicle (C–F and H). +p < 0.05 versus PD128907 + forskolin (A and B), vehicle + dopamine (C–F), or vehicle + SKF81297 (H).Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 433
Neuron
Regulation of D3 Receptors by CaMKIIFigure 8. Disruption of CaMKIIa-D3R Interactions Altered Cocaine-Stimulated Motor Responses
(A) Effects of Tat-fusion peptides on the cocaine-stimulated CaMKIIa-D3R interaction. Rats were sacrificed 20 min after cocaine injection for conducting coim-
munoprecipitation with the P2 fraction from the rat NAc.
(B) Measurements of Tat-D3Rr concentrations in rat striatal tissue. Rats injected with FITC-Tat-D3Rr (3 nmol/g, i.v.) were sacrificed at indicated times.
(C) Neuronal transduction of FITC-Tat-D3Rr, but not FITC-Tat38-48 (3 nmol/g, i.v., 1.5 hr), in the NAc shell region of rat accumbal sections.
(D and E) Systemic Tat-D3Rr attenuated cocaine-stimulated locomotion (D) and had no effect on spontaneous motor activity (E).
(F) A graph of the data from (D) and (E) obtained during 60 min after i.p. injection of drugs.
(G) Intra-accumbal injection of Tat-D3Rr attenuated the cocaine-stimulated locomotion.
(H) Location of microinjection sites within the NAc. Representative sites are illustrated on only one side for the bilateral injections of Tat-D3Rr (right) or
Tat-D3Rt (left).
(I) Tat-D3Rr attenuated the cocaine-stimulated locomotion in WT, but not in D3R mutant, mice.
Cocaine (20mg/kg, i.p.) was injected 60 or 90min after an intra-accumbal injection (15 pmol/0.4 ml) or a systemic injection (3 nmol/g i.v. for rats, and 10 nmol/g i.p.
formice) of Tat peptides, respectively. Data are presented asmeans ±SEM (n = 4–14 per group). *p < 0.05 versus saline + saline. +p < 0.05 versus saline + cocaine.range of evoked dopamine release in striatal slice preparations
(Jones et al., 1998). In separate experiments, the D1R antagonist
SCH23390 blocked the dopamine-stimulated cAMP response
(Figure 7D), indicating that D1R activation largely mediates
the positive cAMP response to dopamine. In contrast to the434 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.D1R antagonist, the highly selective D3R antagonist NGB2904,
when incubated at 50 nM (EC50 of 14.4 nM and 1280.0 nM for
D3 and D2 receptors, respectively; Yuan et al., 1998; Grundt
et al., 2005), slightly increased the cAMP response to dopamine
(although p > 0.05, Figure 7D). NGB2904 alone increased basal
Neuron
Regulation of D3 Receptors by CaMKIIcAMP concentrations, indicating a tonic D3R activity in inhibiting
basal cAMP formation.
CaMKII-D3R interactions further impact downstream effectors
of cAMP/protein kinase A (PKA). In accumbal slices, as shown in
Figure 7E, Tat-D3Rr markedly reduced the dopamine-stimulated
phosphorylation of cAMP-responsive element binding protein
(CREB), a nuclear transcription factor downstream of PKA acti-
vation, in accumbal lysates. Tat-D3Rr also reduced the dopa-
mine-stimulated expression of c-Fos, an immediate early gene
downstreamof CREB (Figure 7F). In addition to CREBand c-Fos,
we examined another target of PKA at excitatory synapses. PKA
phosphorylated AMPA receptor GluR1 subunits at serine 845
(S845) in mouse striatal slices treated with the D1R agonist
SKF81297 (Snyder et al., 2000). Similarly, we observed that
SKF81297 increased protein levels of phospho-GluR1 at S845
(pGluR1-S845) in synaptosomal fractions from rat accumbal
slices (Figure 7G). A higher level of pGluR1-S845 was also
seen in the PSD fraction (Figure 7G), confirming that the event
occurred at synaptic sites. Tat-D3Rr was able to reduce the
SKF81297-stimulated GluR1 phosphorylation in synaptosomes
(Figure 7H), indicating that D3Rs are restored to inhibit the
PKA-mediated GluR1 phosphorylation. Together, our observa-
tions demonstrate that CaMKII inhibits D3R function. As illus-
trated in Figure 7I, under basal conditions, CaMKII interacts
with D3Rs at a low level. D3Rs, due to their higher affinity for
dopamine than D1/D2 receptors (Sokoloff et al., 1992), are acti-
vated by basal levels of dopamine to inhibit adenylyl cyclase.
When dopamine release is enhanced, the inhibitory tone of
D3Rs is suppressed by the Ca2+-induced interaction of CaMKII
with D3RIL3, which, in concert with D1R stimulation, augments
the cAMP/PKA response to dopamine.
A further attempt was made to explore a possible role of our
CaMKIIa-D3R interactionmodel inmodulatinganother keydown-
stream effector of D3Rs. D3Rs expressed in heterologous cells
activate extracellular signal-regulated kinases 1 and 2 (ERK1/2
or p44/p42) via the Gbg pathway (Cussac et al., 1999; Beom
et al., 2004). In HEK293 cells transiently transfected with D3Rs,
we found a similar transient increase in ERK1/2 phosphorylation
following dopamine application (Figure S9A). This was blocked
by NGB2904, confirming the role of D3Rs in mediating this event
(Figure S9B). Noticeably, in HEK293 cells cotransfected with
D3Rs and CaMKIIa, ionomycin (2 mM) reduced the dopamine-
stimulated ERK2 phosphorylation (Figure S9C). Tat-D3Rr, but
not Tat-D3Rt, reversed the effect of ionomycin (Figure S9C). In
accumbal slices, D3Rswere activated by PD128907. This activa-
tion increased ERK2 phosphorylation in synaptosomal fractions,
whichwas reduced by ionomycin (Figure S9D). Tat-D3Rr antago-
nized the effect of ionomycin,while Tat-D3Rtdid not (FigureS9D).
These data indicate that the interaction of CaMKIIa with D3Rs
suppresses the ability of D3Rs to phosphorylate ERK1/2 in heter-
ologous cells and neurons.
CaMKIIa-D3RIL3 Interactions Suppress the D3R-
Mediated Inhibition of Motor Activity
We extended our molecular observations to behavioral experi-
ments to investigate whether regulated CaMKIIa-D3RIL3 interac-
tions modulate behavioral responsiveness to dopamine stimula-
tion. Cocaine is known to stimulate motor activity througha mechanism that results in elevated synaptic dopamine levels.
Given that postsynaptic D3Rs are generally inhibitory to stimu-
lant-induced motor activity (Xu et al., 1997; Bahi et al., 2005;
Richtand, 2006; Pritchard et al., 2007), we speculated that
cocaine would suppress D3Rs by enhancing the interaction of
CaMKIIa with D3Rs, which participates in the regulation of the
motor response to cocaine. Consistent with this model, cocaine
at 20 mg/kg markedly increased the formation of CaMKIIa-
D3RIL3 complexes in the rat NAc (Figure 8A). A slight increase
in this complex formation was induced by cocaine at 5 mg/kg
(19.3% ± 0.03% over control). The effect of cocaine (20 mg/kg)
was blocked by pretreatment with an intravenous (i.v.) injection
of the interfering peptide Tat-D3Rr (3 nmol/g, 1.5 hr before
cocaine). The control peptide (Tat-D3Rt) had no effect. Using
fluorescently tagged peptides (FITC-Tat-D3Rr), the dynamic
presence of these systemically active and cell-permeable
peptides in striatal tissues was demonstrated after a single injec-
tion (Figure 8B). Intracellular uptake of a FITC-Tat-D3Rr peptide,
but not a control peptide containing HIV-1 Tat residues 38 to 48
(KALGISYGRKK; Tat38-48) that lie outside the transduction
domain, was evident in accumbal neurons following an i.v. injec-
tion (Figure 8C). Interestingly, in open field locomotor activity
assays, Tat-D3Rr, but not Tat-D3Rt, reduced the horizontal
activity induced by cocaine (20 mg/kg) while neither peptide
had any effect on spontaneous locomotion (Figures 8D–8F). To
determine whether the effect of systemic peptides primarily
occurs in the local NAc, a microinjection study targeting the
NAc was performed in freely moving rats. A local injection of
Tat-D3Rr (15 pmol, 1 hr prior to cocaine) produced the same
effect as that observed following a systemic injection (Figures
8G and 8H). Additionally, an intra-accumbal injection of KN93,
but not KN92 (10 nmol), reduced the effect of cocaine on the
formation of CaMKIIa-D3R complexes (data not shown). In
WT mice, Tat-D3Rr reduced the cocaine-stimulated locomotion
whereas no such effect was observed in D3R mutant mice
(Figure 8I). Together, these results support a model in which
cocaine recruits CaMKIIa to D3Rs to downregulate the D3R
function in inhibiting motor responses to cocaine, which ulti-
mately enhances behavioral sensitivity to cocaine stimulation.
DISCUSSION
In this study, we uncover a protein-protein interaction between
CaMKIIa and D3Rs in accumbal neurons. The interaction is
region-selective since it did not occur in other brain areas,
including the substantia nigra and the ventral tegmental area.
The interaction involves the consensus CaMKII-binding
sequence (I/L)XRXX(S/T) (White et al., 1998) located in the third
intracellular loop of D3Rs. Another important characteristic of
the CaMKIIa-D3R interaction is its Ca2+ sensitivity. Activation
of CaMKIIa by Ca2+/CaM enhanced the binding affinity of the
kinase for D3Rs in vitro. In accumbal neurons in vivo, activation
of NMDA receptors, VOCCs, and PI-linked D1Rs that elicit the
Ca2+ release from intracellular stores increased the CaMKIIa-
D3R interaction, providing the linkage of these Ca2+ routes to
D3R physiology. Moreover, autophosphorylation of CaMKIIa
regulates the CaMKIIa-D3R interaction. This was shown by the
findings that the autophosphorylation at T286 further enhancedNeuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc. 435
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ciation with D3Rs after Ca2+ was chelated with EGTA. Thus, the
autophosphorylated CaMKIIa is believed to still have an influ-
ence on D3R function even after a transient Ca2+ rise recovers
to the original level.
The NMDA receptor was the first receptor that was identified
to be bound by CaMKIIa at synaptic sites (Gardoni et al., 1998;
Leonard et al., 1999). In response to Ca2+ influx, CaMKIIa is
recruited to thePSDof excitatory synapsesby its increasedasso-
ciationwith theNMDA receptorNR2Bsubunit (Strack et al., 1997;
Colbran, 2004; Bayer et al., 2006). The Ca2+-evoked CaMKIIa-
D3R interaction identified in the current work suggests a new
recruiter of CaMKII to the PSD. This is supported by the distribu-
tion of abundant D3Rs in the purified PSD (this study). The fact
that multiple synaptic receptors interact with CaMKII and recruit
it to presumably distinct submembranous microdomains is in
good accordance with the multivalent and multifunctional nature
of holoenzymes and with the high abundance of the enzyme at
synaptic sites.
The D3RIL3 is a critical region for Gai/o-coupling (Ilani et al.,
2002), and activation of D3Rs inhibits adenylyl cyclase in heter-
ologous cells (Ahlgren-Beckendorf and Levant, 2004; Sokoloff
et al., 2006). In accumbal neurons, the D3R-mediated inhibition
of forskolin-stimulated cAMP accumulation was established in
this study. Notably, the D3R efficacy was subject to the regula-
tion by Ca2+ because the cytoplasmic Ca2+ rise induced by an
ionophore reversed the effect of a D3R agonist. This Ca2+ regu-
lation relies on the CaMKII activation and the subsequent asso-
ciation of activated CaMKII with D3Rs as demonstrated by the
findings that both the CaMKII activation inhibitors (KN93 and
CaMKIINtide) and Tat-D3Rr, which disrupted the CaMKIIa-
D3RIL3 binding, antagonized the effect of the Ca
2+ ionophore.
Together, the Ca2+-triggered recruitment of CaMKII to D3Rs
suppresses the D3R efficacy and thus relieves the inhibitory
tone of D3Rs on the adenylyl cyclase/cAMP cascade. In this
model, a state-dependent nature of CaMKII regulation is recog-
nized (see Figure 7I). Under basal conditions, the regulation is
less significant due to a lower level of CaMKII binding to D3Rs.
As a result, D3Rs become tonically active in inhibiting cAMP
production. Of note, the D3R is the only subtype with an affinity
(Ki = 30 nM; Sokoloff et al., 1992) within the nanomolar range of
basal dopamine concentrations at synapses (50 nM; Ross,
1991). This allows D3Rs to respond to baseline dopamine.
When transformed to a stimulated state in which the synaptic
dopamine level is increased to the micromolar range, CaMKII
is recruited to D3Rs by Ca2+ to depress the D3R efficacy. This,
in concert with the simultaneously activated D1 efficacy in the
same neurons (Surmeier et al., 1996; Ridray et al., 1998), would
produce a net upregulation of the cAMP-PKA pathway and its
downstream effects, including CREB phosphorylation, c-Fos
expression, and AMPA receptor phosphorylation (Snyder et al.,
2000; Zhang et al., 2004; Jiao et al., 2007). The CaMKII-D3R
coupling discovered here suggests a new model of the integra-
tion of limbic dopamine signals under basal and stimulated
conditions.
D1R activation contributes to cocaine-stimulated motor
activity. In response to cocaine, synaptic dopamine levels are
increased, which in turn activates D1Rs on striatonigral neurons.436 Neuron 61, 425–438, February 12, 2009 ª2009 Elsevier Inc.Through cAMP/PKA, D1Rs enhance excitability of these neurons
to glutamate, thereby increasing outflow of the direct striatonigral
pathway and motor activity (Surmeier et al., 2007). In contrast to
D1Rs, D3Rs inhibit the cAMP-PKA pathway. Thus, D3Rs are
believed to exert an inhibitory effect on dopamine-mediated
motor activity. Indeed, D3R mutant mice displayed hyperactivity
in a novel environment (Accili et al., 1996; Xu et al., 1997), indi-
cating an inhibitory tone of postsynaptic D3Rs on normal motor
activity (Koeltzowet al., 1998).D3Rsalsosuppressmotor respon-
siveness to cocaine as evidencedby the fact that cocaine at a low
dose (5 mg/kg) induced a significantly greater motor response in
D3Rmutant mice than in WTmice (Xu et al., 1997). Other behav-
ioral studies utilizing D3R mutant mice or D3R-preferring agents
generally support this view (Bahi et al., 2005; Richtand, 2006;
Pritchard et al., 2007). However, the D3R-mediated inhibition is
subject to downregulation in response to increasing doses of
cocaine because cocaine at higher doses (20–40mg/kg) induced
similar increases in motor responses in D3R mutant mice as
compared to those of WT mice (Xu et al., 1997). Indeed, in this
study, we observed a suppression of D3R function by cocaine
via a mechanism involving CaMKII. This was demonstrated by
the findings that (1) cocaine dose-dependently increased the
association of CaMKII with D3Rs, and (2) the disruption of this
association by Tat-D3Rr restored the ability of D3Rs to suppress
the motor response to cocaine (20 mg/kg) in rats and WT mice,
but not in D3Rmutantmice. Tat-D3Rr also restored the efficiency
of D3Rs to inhibit the D1R-mediated phosphorylation of synaptic
AMPA receptors at a PKA-sensitive site (S845) in accumbal
neurons. Together, through a specific protein-protein interaction
between CaMKII and D3Rs, cocaine transiently releases the
D3R-mediated ‘‘brake’’ on behavioral responses to the stimulant.
This dynamic downregulation of D3R function could enhance
behavioral sensitivity to cocaine stimulation.
EXPERIMENTAL PROCEDURES
Animals
Adult male Wistar rats weighting 200–225 g (Charles River, New York, NY),
adult WT mice, and mutant mice lacking D3Rs were individually housed at
23C and humidity of 50% ± 10% with food and water available ad libitum.
The animal room was on a 12/12 hr light/dark cycle with lights on at 0700.
All animal use procedures were in strict accordance with the NIH Guide for
the Care andUse of Laboratory Animals andwere approved by the Institutional
Animal Care and Use Committee.
Protein Extraction
Animals were anesthetized with 2.5%–3% isoflurane and decapitated. Brains
were removed and coronal sections were cut. Bilateral punches of the local
NAc (core and shell) or other brain regions were obtained using punch corers.
Samples were removed into a microtube containing ice-cold sample buffer
(20 mM Tris-HCl [pH 7.4], 1 mM dithiothreitol, 10 mM NaF, 2 mM Na3VO4,
1 mM EDTA, 1 mM EGTA, 5 mMmicrocystin-LR, and 0.5 mM phenylmethylsul-
fonyl fluoride), and homogenized by sonication. Homogenates were centri-
fuged at 700 3 g for 10 min at 4C. The supernatant was centrifuged at
10,000 3 g at 4C for 30 min to obtain the P2 pellet (synaptosomal fraction).
The P2 was soluabilized (see Supplemental Experimental Procedures). Protein
concentrations in homogenates (lysates) and the P2 pellet were determined.
Cloning, Expression, and Purification of GST-Fusion Proteins
The cDNA fragments encoding the D3RIL2(D127-R149), D3RIL3(R210-Q375),
D3RIL3(R210-P239), D3RIL3(Q240-Q375), D3RIL3(H269-Q375), D3RIL3(R345-
Q375), D2RIL3(I210-V270), CaMKIIaCD(L91-S272), CaMKIIaRD(H273-S314),
Neuron
Regulation of D3 Receptors by CaMKIIor CaMKIIaAD(G315-H478) were generated by PCR amplification from
full-length cDNA clones. These fragments were subcloned into BamHI-EcoRI
sites of the pGEX4T-3 plasmid (Amersham Biosciences, Arlington Heights, IL)
or SpeI-XhoI sites of the pET-41a(+) plasmid (Novagen, Madison, WI). Initiation
methionine residues and stop codons were also incorporated where appro-
priate. To confirm appropriate splice fusion, all constructs were sequenced.
GST-fusion proteins were expressed in E. coli BL21 cells (Amersham) or
BL21(DE3)pLysE cells (Novagen) and purified from bacterial lysates as
described by the manufacturer. GST- or His-tagged full-length CaMKIIa
(M1-H478) and GST-tagged full-length CaMKIV (M1-Y473) were expressed
and purified via a baculovirus/Sf9 insect cell expression system.
Affinity Purification (Pull-Down) Assay
Solubilized accumbal extracts (50–100 mg of protein) were diluted with 1X
PBS/1% Triton X-100 and incubated with 50% (v/v) slurry of glutathione
Sepharose 4B beads (Amersham) saturated with GST alone or with the indi-
cated GST-fusion protein (5–10 mg) for 2–3 hr at 4C. Beads were washed
four times with 1X PBS/1% Triton X-100. Bound proteins were eluted with
2X lithium dodecyl sulfate (LDS) sample buffer, resolved by SDS-PAGE, and
immunoblotted with a specific antibody.
In Vitro Binding Assay
GST-fusion proteins (1–5mg) in PBSwere digestedwith 0.2NIHunit of thrombin
(Sigma, St. Louis, MO) for 2 hr at room temperature. The reaction was stopped
by adding PMSF (10 mM). GST was removed by glutathione Sepharose (Amer-
sham). The supernatant was equilibrated to binding buffer (200 mM NaCl,
0.2% Triton X-100, 0.1 mg/ml BSA, and 50 mM Tris [pH, 7.5]) with or without
0.5 mM CaCl2, 1 mM CaM, 1 mM EGTA, or 50 mM ATP as indicated. In some
experiments, His-tagged CaMKIIa WT (57 kDa), WT pCaMKIIa, CaMKIIa
mutants (50 kDa), or CaMwas used. Binding reactions were initiated by add-
ing purified GST-fusion proteins and were remained at 4C for 2–3 hr unless
otherwise indicated. GST-fusion proteins were precipitated using 100 ml of
10% glutathione Sepharose. The precipitate was washed three times with
bindingbuffer. Boundproteinswere elutedwith 2XLDS loadingbuffer, resolved
by SDS-PAGE, and immunoblotted with a specific antibody.
cAMP Enzyme Immunoassay
After incubation with drugs indicated for 20–30 min at room temperature,
accumbal slices were homogenized in 0.1MHCl solution for 15min with gentle
shaking and spun in the microcentrifuge tubes. cAMP concentration of the
supernatant was measured using the Direct cAMP Enzyme Immunoassay
(EIA)Kit (AssayDesigns,AnnArbor,MI) following themanufacturer’s instruction.
Protein concentrationswere determined using aBCAProtein Assay kit (Pierce).
Behavioral Assessments
Locomotion in an open field was evaluated as described previously (Liu
et al., 2006).
SUPPLEMENTAL DATA
The supplemental data for this article include nine Supplemental Figures and
Supplemental Experimental Procedures and can be found at http://www.
neuron.org/supplemental/S0896-6273(08)01086-6.
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